Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Molecular Cancer Therapeutics|April 8, 2018
BRAF Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK InhibitorsCamilla Stagni, Carolina Zamuner, Lisa Elefanti, et al.
International Journal of Molecular Sciences|August 12, 2023
Molecular Modeling Unveils the Effective Interaction of B-RAF Inhibitors with Rare B-RAF Insertion VariantsMaria Chiara Scaini, Luisa Piccin, Davide Bassani, et al.
Clinical and Experimental Dermatology|November 10, 2025
Identifying High-Risk Features and Improving Follow-Up Strategies in Thin Melanoma: A Retrospective Cohort StudyAntonella Vecchiato, Claudia Cozzolino, Paolo Del Fiore, et al.
Pathologica|April 9, 2026
Immunohistochemical and molecular profiling of uveal melanoma: clinicopathological correlations from an Italian cohortFrancesco Fortarezza, Giovanni Zarrilli, Giada Munari, et al.
Cancers|May 27, 2026
New Perspectives and Open Issues in the Adjuvant and Neoadjuvant Treatment of MelanomaAndrea Spagnoletti, Lorenza Di Guardo, Alice Indini, et al.
Cancers|December 17, 2024
Retrospective-Prospective Observational Study of Italian Patients Treated in Melanoma Adjuvant Cohort MAP-MADAM (Maximing ADjuvAnt MAP): Interim AnalysisFrancesca Consoli, Marco Tucci, Jacopo Pigozzo, et al.
The American Journal of Dermatopathology|April 15, 2026
Clinicopathologic Features and Treatment Outcomes of Squamoid Eccrine Ductal Carcinoma: A Comprehensive Retrospective SeriesFrancesco Fortarezza, Laura Gnesotto, Paolo Del Fiore, et al.
Cancers|June 12, 2026
Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future DirectionsFederico Pravisano, Jacopo Costa, Lorenzo De Marchi, et al.
NPJ Precision Oncology|March 29, 2024
A multiparameter liquid biopsy approach allows to track melanoma dynamics and identify early treatment resistanceMaria Chiara Scaini, Cristina Catoni, Cristina Poggiana, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 3, 2012
The cost of unresectable stage III or stage IV melanoma in ItalyMichele Maio, Paolo Ascierto, Alessandro Testori, et al.
Pageof 6